Formulation of Liver-Specific PLGA-DY-635 Nanoparticles Loaded with the Protein Kinase C Inhibitor Bisindolylmaleimide I
- Supplementary File 1:
PDF-Document (PDF, 295 KiB)
Shkodra, B.; Press, A.T.; Vollrath, A.; Nischang, I.; Schubert, S.; Hoeppener, S.; Haas, D.; Enzensperger, C.; Lehmann, M.; Babic, P.; Benecke, K.J.; Traeger, A.; Bauer, M.; Schubert, U.S. Formulation of Liver-Specific PLGA-DY-635 Nanoparticles Loaded with the Protein Kinase C Inhibitor Bisindolylmaleimide I. Pharmaceutics 2020, 12, 1110. https://doi.org/10.3390/pharmaceutics12111110
Shkodra B, Press AT, Vollrath A, Nischang I, Schubert S, Hoeppener S, Haas D, Enzensperger C, Lehmann M, Babic P, Benecke KJ, Traeger A, Bauer M, Schubert US. Formulation of Liver-Specific PLGA-DY-635 Nanoparticles Loaded with the Protein Kinase C Inhibitor Bisindolylmaleimide I. Pharmaceutics. 2020; 12(11):1110. https://doi.org/10.3390/pharmaceutics12111110
Chicago/Turabian StyleShkodra, Blerina, Adrian T. Press, Antje Vollrath, Ivo Nischang, Stephanie Schubert, Stephanie Hoeppener, Dorothee Haas, Christoph Enzensperger, Marc Lehmann, Petra Babic, Kay J. Benecke, Anja Traeger, Michael Bauer, and Ulrich S. Schubert. 2020. "Formulation of Liver-Specific PLGA-DY-635 Nanoparticles Loaded with the Protein Kinase C Inhibitor Bisindolylmaleimide I" Pharmaceutics 12, no. 11: 1110. https://doi.org/10.3390/pharmaceutics12111110